New executive director of the Global Fund outlines ambitious agenda

21 January 2013

Mark Dybul yesterday took charge as executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, promising to accelerate the organization’s efforts to defeat these three highly infectious diseases by working closely with partners.

Dr Dybul, formerly a co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law at Georgetown University and named to the new post last fall (The Pharma Letter November 16, 2012), may be best known for playing a key role in creating, and later leading, PEPFAR - the largest global health initiative ever undertaken to address a single disease, which is widely credited with helping reverse the trend of AIDS, reducing new infection in many countries.

Dr Dybul outlined an ambitious and energetic agenda for the coming year. The Global Fund will launch a new funding model in February, allowing it to invest more strategically, engage implementers and partners more effectively and achieve greater impact in a way that improves the health and the lives of women and men and children all over the world.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical